Kura Oncology
KURA
133 hedge funds and large institutions have $687M invested in Kura Oncology in 2023 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 64 increasing their positions, 34 reducing their positions, and 24 closing their positions.
88% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 34
0.05% more ownership
Funds ownership: 101.41% → 101.46% (+0.05%)
10% less funds holding
Funds holding: 148 → 133 (-15)
14% less capital invested
Capital invested by funds: $795M → $687M (-$108M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
63% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 24
77% less call options, than puts
Call options by funds: $201K | Put options by funds: $892K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$11.5M |
| 2 |
BlackRock
New York
|
+$7.75M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$5.98M |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$3.12M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$9.17M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$7.42M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$5.29M |
| 4 |
Goldman Sachs
New York
|
-$4.77M |
| 5 |
EP
Eversept Partners
New York
|
-$4.77M |
KURA Hedge Fund Activity: Q3 2023 in Review
133 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q3 2023, worth a combined $687M — down 14% from $795M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of KURA and 9 opened new positions — a net loss of 15 holders — while 34 trimmed existing stakes and 64 added.
The largest buyer was Deerfield Management, adding an estimated $11.5M. The largest seller was Woodline Partners, exiting entirely with an estimated $9.17M sold.
- 133 institutional investors held Kura Oncology (KURA) as of Q3 2023, down from 148 in Q2 2023.
- Funds reported $687M of Kura Oncology stock for Q3 2023, down 14% quarter-over-quarter.
- 9 funds opened new Kura Oncology positions in Q3 2023 and 24 closed out, a net change of -15 holders.
- The largest Kura Oncology buyer in Q3 2023 was Deerfield Management, an estimated $11.5M added.
- The largest Kura Oncology seller in Q3 2023 was Woodline Partners, an estimated $9.17M sold.
Based on aggregated 13F filings for Q3 2023.